We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Yourgene Health Receives HSA Approval for IONA Nx NIPT Workflow in Singapore

Yourgene Health Receives HSA Approval for IONA Nx NIPT Workflow in Singapore content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Yourgene Health plc (“Yourgene”, AIM: YGEN) has announced it has received Health Sciences Authority (HSA) approval for its IONA® Nx NIPT Workflow in Singapore. The prenatal screening workflow has been authorised for use in clinical laboratories, providing them with a fully automated and cost-effective testing solution to establish their own fast, accurate and quality-assured non-invasive prenatal testing (NIPT) service. Yourgene’s optimised NIPT solution enables efficient workflows, helping to save laboratories time, money and enhance their performance.

The IONA Nx NIPT Workflow is an in vitro diagnostic (IVD) tool designed to offer flexibility, simplicity and scalability for prenatal screening. The fully validated workflow uses next-generation sequencing (NGS)-based whole genome analysis to screen for a wide range of clinical conditions in the fetus, including Down’s syndrome (Trisomy 21), Edwards' syndrome (Trisomy 18) or Patau’s Syndrome (Trisomy 13). It can also be used to screen for autosomal- and sex-chromosome aneuploidies, as well as providing the option of fetal sex determination from 10 weeks gestation. The complete workflow includes sample preparation, DNA extraction and library construction, requiring minimal fetal fraction, as well as sequencing analysis and clinical reporting with full sample traceability.

The approval of the workflow in Singapore will help to expand patient access to non-invasive prenatal screening and provide laboratories with choice as to which IVD NIPT services they are able to offer clinicians. The regulatory authorisation adds to the IONA Nx’ existing accreditations, including a CE mark, and now means the workflow is available in many countries across Europe, the Middle East and Asia.

Rob Henke, PhD, Vice President of Sales, Asia Pacific, Yourgene Health, said:By expanding into Singapore’s market, we are able to provide more laboratories access to our technology and, ultimately, offer more patients NIPT as a first call over higher risk procedures. Expanding further into Asia, with the help of our distributor SDT Molecular, is an exciting milestone for Yourgene, as we continue to establish new revenue opportunities and grow our international customer base.”

Shirley Tan, CEO of SDT Molecular, added: We are honoured to be given the opportunity to help Yourgene obtain HSA approval for their IVD NIPT solution in Singapore. This marks an important milestone for SDT Molecular and we look forward to working closely with Yourgene, to allow more clinical laboratories in the region to benefit from this IVD offering.